Ethyl methyl hydroxypyridine succinate
1 ml of 1 amp. 2 ethyl-6-methyl-3-hydroxypyridine succinate 50 mg 100 mg.
An inhibitor of free radical processes is a membrane protector, which also has an antihypoxic, stress-protective, nootropic, anti-epileptic and anxiolytic effect. Belongs to the class of 3-hydroxypyridines. The mechanism of action is due to antioxidant and membrane-protective properties. Suppresses the FLOOR, increases the activity of superoxidase, increases the ratio of lipid-protein, improves the structure and function of the cell membrane. Modulates the activity of membrane enzymes (Ca2 + -independent PDE, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine), which contributes to ligand binding, preservation of structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. Increases the concentration in the brain dopamine. It enhances the compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in ATP and creatine phosphate, activates the energy-synthesizing function of mitochondria. Increases the body's resistance to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with ethanol and antipsychotic drugs). It improves the metabolism and blood supply of the brain, microcirculation and rheological properties of the blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and LDL. Improves the functional state of the ischemic myocardium during myocardial infarction, contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the LV. Under conditions of critical reduction of coronary blood flow, it contributes to the preservation of the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes - PDE, adenylate cyclase, acetylcholinesterase.It supports the activation of aerobic glycolysis, which develops during acute ischemia, and, under hypoxic conditions, supports the reduction of mitochondrial redox processes, increases the synthesis of ATP and creatine phosphate. Ensures the integrity of the morphological structures and physiological functions of the ischemic myocardium. It improves the clinical course of myocardial infarction, increases the effectiveness of therapy, speeds up the restoration of the functional activity of the LV myocardium, reduces the incidence of arrhythmias and disorders of intracardiac conduction. Normalizes metabolic processes in ischemic myocardium, reduces the area of necrosis, restores and / or improves electrical activity and myocardial contractility, and also increases coronary blood flow in the ischemic zone, increases antianginal activity of nitrodrugs, improves the rheological properties of blood, reduces the effects of reperfusion syndrome in acute coronary insufficiency. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
- anxiety states in neurotic and neurosis-like states. - Vegetative-vascular dystonia. - encephalopathy . - slight cognitive disorders of atherosclerotic genesis. - acute disorders of cerebral circulation (as part of combination therapy). - withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders. - acute intoxication with antipsychotic drugs. - acute purulent-inflammatory processes in the abdominal cavity (including acute necrotic pancreatitis, peritonitis (as part of complex therapy)). - acute myocardial infarction from the first day (parenteral). - CHD. - complex therapy of ischemic stroke (orally) - as part of complex therapy.
- hypersensitivity - acute hepatic and / or renal failure - pregnancy - lactation period - children's age. C caution: in the presence of allergic diseases in history (for parenteral administration).
Use during pregnancy and lactation
Contraindicated in pregnancy, during lactation.
Dosage and administration
Mexidol, Meksidant Inside, 0.25-0.5 g / day in 2-3 doses. the maximum daily dose is 0.6-0.8 g. The duration of treatment is 2-6 weeks. for stopping alcohol withdrawal - 5-7 days.Treatment is stopped gradually, reducing the dose within 2-3 days. V / m, v / v (jet, for 5-7 min or drip, with a speed of 60 drops / min). When the infusion method of administration is diluted in 200 ml of 0.9% sodium chloride solution. The initial dose - 0.05-0.1 g 1-3 times / day with a gradual increase to obtain a therapeutic effect. The maximum daily dose is 0.8 g. In acute cerebrovascular accidents - intravenous drip, 0.2-0.3 g 1 time / day for the first 2-4 days, then v / m, 0.1 g 3 times / day. When dyscirculatory encephalopathy (decompensation phase) - in / in jet or drip, 0.1 g 2-3 times / day for 14 days, and then in / m, 0.1 g for 14 days. With course prophylaxis of dyscirculatory encephalopathy - i / m, 0.1 g 2 times / day for 10-14 days. IRR, neurotic and neurosis-like states - in / m, at 0.05-0.4 g / day for 14 days. With withdrawal syndrome - in / m, 100-200 mg 2-3 times / day or / drip, 1-2 times / day for 5-7 days. For acute intoxication with antipsychotics - in / in 0.05-0.3 g / day for 7-14 days. In mild cognitive disorders - in / m at 0.1-0.3 g / day for 14-30 days. During purulent-inflammatory processes in the abdominal cavity (acute necrotic pancreatitis, peritonitis) - on the first day in the preoperative and postoperative period. The dose depends on the form and severity of the disease, the prevalence of the process, the clinical course. The abolition of the drug is made gradually after sustained clinical and laboratory improvement. For acute edematous (interstitial) pancreatitis of mild severity - 0.1-0.2 g 3 times / day in / in the drip and in / m. moderate severity - 0.2 g 3 times / day. in case of severe course - in / in drip, 0.8 g on the first day (divided into 2 injections), then - 0.3 g 2 times / day with a gradual decrease in the daily dose. extremely severe course - in / in drip, at 0.8 g / day until persistent relief of symptoms of pancreatic shock. after stabilization of the state - 0.3-0.4 g 2 times / day with a gradual decrease in the daily dose. With myocardial infarction - in / in (in the first 5 days) and in / m (the next 9 days) 3 times / day (every 8 hours). Daily dose - 6-9 mg / kg / day, single dose - 2-3 mg / kg. The maximum daily dose should not exceed 800 mg, single - 250 mg. In / injected infusion for 30-90 minutes in 100-150 ml of a 0.9% solution of sodium chloride or 5% dextrose or jet for at least 5 minutes. When ischemic heart disease: inside, 100 mg 3 times / day. Course duration at least 2 months. if necessary, repeat courses are possible.
Nausea, dry mouth, diarrhea, drowsiness, allergic reactions.When administered parenterally (especially in / in the jet): dry, "metallic" taste in the mouth, feeling of "spill heat" in the whole body, unpleasant smell, sore throat and discomfort in the chest, feeling of lack of air (usually associated with excessive high rate of administration and are short term). with prolonged use - nausea, flatulence. sleep disturbances (drowsiness or sleep disturbance).
Nausea, dry mouth, diarrhea, drowsiness, allergic reactions. When administered parenterally (especially in / in the jet): dry, "metallic" taste in the mouth, feeling of "spill heat" in the whole body, unpleasant smell, sore throat and discomfort in the chest, feeling of lack of air (usually associated with excessive high rate of administration and are short term). with prolonged use - nausea, flatulence. sleep disturbances (drowsiness or sleep disturbance).